BDMC combined with icotinib exhibits potent, synergistic growth suppression in EGFR-TKI-resistant NSCLC via multiple pathways, such as ROS accumulation, autophagy induction, or DNA damage [147]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.